These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36943159)

  • 41. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
    Hopkins CY; Gilchrist BL
    J Emerg Med; 2013 Oct; 45(4):544-6. PubMed ID: 23890687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ["Spice"--synthetic cannabinoids with dangerous effects].
    Personne M; Westerbergh J; Hammer-Pettersen L
    Lakartidningen; 2014 Nov; 111(47):2105-7. PubMed ID: 25386644
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro determination of the efficacy of illicit synthetic cannabinoids at CB
    Sachdev S; Vemuri K; Banister SD; Longworth M; Kassiou M; Santiago M; Makriyannis A; Connor M
    Br J Pharmacol; 2019 Dec; 176(24):4653-4665. PubMed ID: 31412133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.
    Kevin RC; Cairns EA; Boyd R; Arnold JC; Bowen MT; McGregor IS; Banister SD
    Front Psychiatry; 2022; 13():1048836. PubMed ID: 36590635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids.
    White CM
    J Clin Pharmacol; 2017 Mar; 57(3):297-304. PubMed ID: 27610597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Synthetic Cannabinoids Phenomenon.
    Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
    Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthetic cannabinoid receptor agonists-induced recurrent seizure in elderly patient.
    Andreias L; Roffe E; Eng A; Yiu K; Pashmforoosh G; Khan Z; Rahman R; Kalantari H; Hassen GW
    Am J Emerg Med; 2020 Apr; 38(4):850.e5-850.e6. PubMed ID: 31839517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms for the Risk of Acute Coronary Syndrome and Arrhythmia Associated With Phytogenic and Synthetic Cannabinoid Use.
    Richards JR
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):508-522. PubMed ID: 32588641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.
    Glatfelter GC; Partilla JS; Baumann MH
    Neuropsychopharmacology; 2022 Mar; 47(4):924-932. PubMed ID: 34802041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC.
    Kruger DJ; Kruger JS
    Cannabis Cannabinoid Res; 2023 Feb; 8(1):166-173. PubMed ID: 34797727
    [No Abstract]   [Full Text] [Related]  

  • 54. Synthetic Cannabinoids.
    Mills B; Yepes A; Nugent K
    Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
    Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
    Lea Houston M; Morgan J; Kelso C
    Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine.
    Wouters E; Mogler L; Cannaert A; Auwärter V; Stove C
    Drug Test Anal; 2019 Aug; 11(8):1183-1191. PubMed ID: 31021521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.
    Pacher P; Steffens S; Haskó G; Schindler TH; Kunos G
    Nat Rev Cardiol; 2018 Mar; 15(3):151-166. PubMed ID: 28905873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.
    Bidwell LC; Karoly HC; Torres MO; Master A; Bryan AD; Hutchison KE
    Psychopharmacology (Berl); 2022 Feb; 239(2):385-397. PubMed ID: 34708254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?
    Ametovski A; Cairns EA; Grafinger KE; Cannaert A; Deventer MH; Chen S; Wu X; Shepperson CE; Lai F; Ellison R; Gerona R; Blakey K; Kevin R; McGregor IS; Hibbs DE; Glass M; Stove C; Auwärter V; Banister SD
    ACS Chem Neurosci; 2021 Nov; 12(21):4020-4036. PubMed ID: 34676751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.